PDCD1 and cancer: There has been substantial clinical evidence that the survival of patients with advanced cancer is improved by immune checkpoint inhibitors (ICIs), especially by blocking the immune checkpoint axis involved in programmed cell death 1 (PD-1) and programmed death ligand 1 (PD-L1)195,196.